Clinical management of refractory prolactinomas:stone to sharpen yan,blunt for profit
10.11855/j.issn.0577-7402.0201.2024.0820
- VernacularTitle:难治性催乳素瘤的临床应对:石以砥焉,化钝为利
- Author:
Rui-Feng WANG
1
,
2
;
Xiao-Zhen YE
;
Jian-Rui LI
;
Jing LI
;
Jia-Liang LI
;
Zi-Xiang CONG
;
Yan LU
;
Nan WU
;
Yi-Feng GE
;
Chi-Yuan MA
;
Jia-Qing SHAO
Author Information
1. 东部战区总医院内分泌科,江苏 南京 210002
2. 东部战区总医院垂体瘤协作组,江苏 南京 210002
- Keywords:
refractory prolactinoma;
dopamine;
clinical treatment
- From:
Medical Journal of Chinese People's Liberation Army
2024;49(11):1237-1243
- CountryChina
- Language:Chinese
-
Abstract:
Refractory prolactinoma is the most common pituitary neuroendocrine tumor.Dopamine receptor agonists(DA)are the primary choice for drug treatment.Most patients with prolactinomas respond well to DA.However,a minority of prolactinomas patients still show resistance to DA.Although drug-resistant and refractory prolactinomas are rare in clinical practice,their treatment is extremely challenging.Even a combination of drug therapy,multiple surgeries,and radiotherapy may not yield satisfactory outcomes.Therefore,standardizing the diagnosis and treatment process and pathway for refractory prolactionmas and exploring more effective multidisciplinary collaborative treatment strategies are urgent problems to be solved.In the clinical management of refractory prolactinomas,it is often necessary to consider the patient's condition comprehensively,replace other types of DA,or consider surgery,radiotherapy,and immunotherapy,which requires multidisciplinary diagnosis and treatment.This review synthesizes the latest literature at home and abroad to systematically discuss the latest advances in drug therapy,surgery,and radiotherapy treatments for refractory prolactionmas,aiming to provide new ideas for basic research,clinical diagnosis and treatment.
